Preliminary anti-tumor activity for lead asset, monalizumab, in combination with cetuximab in advanced head and neck cancer and durvalumab in microsatellite-stable colorectal cancer presented at...

IPH5401 is a first-in-class antibody targeting the C5a receptor expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment IPH5401 combined with PD-1...

Updated long term follow-up data and new data from cohort expansion in the Phase I of IPH4102 in advanced CTCL at the EORTC CLTF 2018 Meeting Updated data from Phase I/II fully-enrolled study of...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced a change to its 2018 financial calendar. The financial statements as of June 30, 2018 will be issued on September...

Updated clinical data show preliminary anti-tumor activity in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on May 29, 2018, in Marseille, France...

Preliminary activity observed in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1 blockade 3 partial responses...

Cash, cash equivalents and financial assets of the Company amounted to €153.8 million* Significant momentum across the portfolio, with good progress on the joint monalizumab program with AstraZeneca...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 29, 2018, at 10:00 am in its headquarters, 117 avenue de Luminy...

8 partial responses (PR) among 26 patients evaluable for efficacy – predefined number of responses needed to declare the trial result positive has been reached The combination was well tolerated...